Sayyad, Nusrat B. <br/><br/>
Aromatase inhibitors: development and current perspectives 

 - Vol.56(2), Apr-June 
 - Karnataka  Association of Pharmaceutical Teachers of India (APTI)  2022 
 - 311-320p. 
<br/><br/> Aim: Breast cancer is one of the most common cancers among women, consistently<br/>elevated estrogen level in the blood associated with persistently in breast cancer found in<br/>many studies. The mechanisms of carcinogenesis whereby cancer is associated involved<br/>in the conversion of androgen to estrogen in the presence of enzyme aromatase. Materials<br/>and Methods: Aromatase is a (CYP19), a cytochrome P450, which is the enzyme that<br/>synthesizes estrogen. Aromatase which is expressed in higher concentration in breast<br/>play a pivotal role in the origin and progression of breast cancer.<br/>In situ inhibition of<br/>aromatase enzyme accomplished by the prevention of aromatase expression in breast<br/>cancer. Results: The success of aromatase inhibition could result in the suppression and<br/>progression of breast cancer. One of the ways to reduce the incidence of breast cancer by<br/>inhibiting estrogen biosynthesis in breast tissue. Aromatase inhibitor therapy is considered<br/>for second-line treatment in patients who fail anti-estrogen therapy. Conclusion: Several<br/>potent and selective aromatase inhibitors have been developed and used to treat breast<br/>cancer. Some of them have passed clinical trial phase II. Development in the field has<br/>encouraged us to review work on the Aromatase inhibitor. 
<br/><br/><label>Subjects--Topical Terms: </label><br/>PHARMACEUTICS